Inhibition of IgE-receptor interactions

British Medical Bulletin

Volumn 56, Issue 4, 2000, Pages 1004-1018

  Sutton, Brain J ^a   Beavil, Rebecca L ^a   Beavil, Andrew J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD23 ANTIGEN; FC RECEPTOR; IMMUNOGLOBULIN E RECEPTOR;

ALLERGY; CRYSTAL STRUCTURE; MAST CELL; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; REVIEW; STRUCTURE ANALYSIS;

ALLERGENS; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; FEEDBACK; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN E; IMMUNOTHERAPY; PROTEIN BINDING; PROTEIN STRUCTURE, QUATERNARY; RECEPTORS, IGE;

EID: 0034445832     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1258/0007142001903508     Document Type: Review

References (53)

1. The human IgE network
2. CD21 is a ligand for CD23 and regulates IgE production
3. A new role for CD23 in inflammation
4. IgE and IgE Receptors
5. The high-affinity IgE receptor (FcεRI); from physiology to pathology
6. Consequences of IgE/CD23-mediated antigen presentation in allergy
7. IgE homeostasis: Is CD23 the safety switch?
8. Structure of the Fc fragment of human IgE bound to its high-affinity receptor FcεRIα
9. Inhibition of an in vivo antigen-specific IgE response by antibodies to CD23
10. Critical role of CD23 in allergen-induced bronchoconstriction in a murine model of allergic asthma
11. In vitro IgE inhibition in B-cells by anti-CD23 monoclonal antibodies is functionally dependent on the immunoglobulin Fc domain
12. CD23 (FcεRII) release from cell membranes is mediated by a membrane-bound metalloprotease
13. Native and recombinant soluble CD23 fragments with IgE suppressive activity
14. Soluble CD21 (sCD21) forms biologically active complexes with CD23: sCD21 is present in normal plasma as a complex with trimeric CD23 and inhibits soluble CD23-induced IgE synthesis by B-cells
15. IgE secretion is attenuated by an inhibitor of proteolytic processing of CD23 (FcεRII)
16. A mite subversive: Cleavage of CD23 and CD25 by Der p1 enhances allergenicity
17. Conformations of IgE bound to its receptor FcεRI and in solution
18. Bent domain structure of recombinant human IgEFc in solution by X-ray and neutron scattering in conjunction with an automated curve fitting procedure
19. Peptide inhibition of the Prausnitz-Küstner reaction
20. Failure of the putative IgE pentapeptide to compete with IgE for receptors on basophils and mast cells
21. The mast cell binding site on human immunoglobulin E
22. Blocking of passive sensitization of human mast cells and basophil granulocytes with IgE antibodies by a recombinant human ε-chain fragment of 76 amino acid residues
23. Participation of the N-terminal region of Cε3 in the binding of human IgE to its high affinity receptor FcεRI
24. Inhibition of human IgE synthesis by anti-IgE antibodies requires divalent recognition
25. Inhibition of IgE synthesis by anti-IgE: Role in long-term inhibition of IgE synthesis by neonatally administered soluble IgE
26. Regulation of IgE-mediated inflammation by soluble fragments of the high affinity IgE receptor
27. An epitope on membrane-bound but not secreted IgE: Implications in isotype-specific regulation
28. Allergy treatment with a peptide vaccine
29. Oral anti-IgE immunization with epitope-displaying phage
30. Profound reduction in allergen sensitivity following treatment with a novel allergy vaccine
31. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: Efficacy, safety and pharmacokinetics
32. IgE inhibition as a therapy for allergic disease
33. The pharmacological basis of anti-IgE therapy
34. Down-regulation of Fc≠RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody
35. Inhibition of allergic reactions with antibodies to IgE
36. Recombinant soluble form of the human high-affinity immunoglobulin E (IgE) receptor inhibits IgE production through its specific binding to IgE-bearing B-cells
37. Up-regulation of FcεRI on human basophils by IgE antibody is mediated by interaction of IgE with FcεRI
38. FcεRI-expressing antigen-presenting cells: New players in the atopic game
39. Fcε receptor I on dendritic cells delivers IgE-bound multivalent antigens into a cathepsin S-dependent pathway of MHC class II presentation
40. Crystal structure of the human high-affinity IgE receptor
41. Structure based design and characterization of peptides that inhibit IgE binding to its high-affinity receptor
42. Monoclonal antibodies and synthetic peptides define the active site of FcεRI and a potential receptor antagonist
43. Human IgE receptor α-chain IgG chimera blocks passive cutaneous anaphylaxis reaction in vivo
44. Identification of contact residues in the IgE binding site of human FcεRIcα
45. Fine structure analysis of interaction of FcεRI with IgE
46. Production of a chimeric form of CD23 that is oligomeric and blocks IgE binding to the FcεRI
47. The binding site on human immunoglobulin E for its high affinity receptor
48. Identification of the high affinity receptor binding region in human immunoglobulin E
49. Structure of the human IgE-Fc Cε3-Cε4 reveals conformational flexibility in the antibody effector domains
50. Convergent solutions to binding at a protein-protein interface
51. High-affinity oligonucleotide ligands to human IgE inhibit binding to Fcε receptor I
52. Inhibition of the binding of human IgE to its receptor by tetracyclic compounds for the alleviation of IgE-mediated immune response
53. Thermodynamics of the interaction of human immunoglobulin E with its high-affinity receptor FcεRI